Review article: Current treatment options and management of functional dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 1, 2012, Pages 3-15

  Lacy, B E ^a   Talley, N J ^b   Locke III, G R ^c   Bouras, E P ^d   Dibaise, J K ^e   El Serag, H B ^f   Abraham, B P ^f   Howden, C W ^g   Moayyedi, P ^h   Prather, C ⁱ  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

^e MAYO CLINIC   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

ⁱ SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOTIAMIDE; ALEMCINAL; AMITRIPTYLINE; ANTINOCICEPTIVE AGENT; CISAPRIDE; DEXLOXIGLUMIDE; DOMPERIDONE; DULOXETINE; ESOMEPRAZOLE; GABAPENTIN; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; ITOPRIDE; LANSOPRAZOLE; MOSAPRIDE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PREGABALIN; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PRUCALOPRIDE; RANITIDINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; BEHAVIOR THERAPY; CARDIOTOXICITY; CHRONIC PAIN; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONSTIPATION; DEPRESSION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; GASTROESOPHAGEAL REFLUX; GENERALIZED ANXIETY DISORDER; HEARTBURN; HELICOBACTER PYLORI; HUMAN; IRRITABLE COLON; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PATHOGENESIS; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SOCIAL SUPPORT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANALGESICS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; DYSPEPSIA; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 84861799493     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05128.x     Document Type: Review

References (97)

1. Camilleri M, Dubois D, Coulie B, et al,. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3: 543-52.
2. El-Serag HB, Talley NJ,. Systematic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643-54.
3. Castillo EJ, Camilleri M, Locke GR III, et al,. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004; 2: 985-96.
4. Ford AC, Forman D, Bailey AG, et al,. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut 2007; 56: 321-7.
5. Tack J, Talley NJ, Camilleri M, et al,. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
6. Choung RS, Locke GR, Schleck CD, et al,. Do distinct dyspepsia subgroups exist in the community? A population-based study Am J Gastroenterol 2007; 102: 1983-9.
7. Bisschops R, Karamanolis G, Arts J, et al,. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 2008; 57: 1495-503.
8. Tack J, Bisschops R, Sarnelli G,. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-55.
9. Talley NJ, Vakil NB, Moayyedi P,. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80.
10. Lacy BE, Cash BD,. A 32-year-old woman with chronic abdominal pain. JAMA 2008; 299: 555-65.
11. El-Serag HB, Talley NJ,. Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 387-93.
12. Moayyedi P, Mason J,. Clinical and economic consequences of dyspepsia in the community. Gut 2002; 50 (Suppl. IV): 10-2.
13. Brook RA, Kleinman NL, Choung RS, et al,. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010; 8: 498-503.
14. Matsueda K, Hongo M, Tack J, et al,. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2011; gutnjl-2011-301454.
15. Piessevaux H, De Winter B, Loouis E, et al,. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol Motil 2009; 21: 378-88.
16. Pilichiewicz AN, Horowitz M, Holtmann GJ, Talley NJ, Feinle-Bisset C,. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2009; 7: 317-22.
17. Saito YA, Locke GR, Weaver AL, Zinsmeister AR, Talley NJ,. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol 2005; 100: 2743-8.
18. Barbera R, Feinle C, Read NW,. Nutrient specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995; 40: 1636-41.
19. Feinle C, Meier O, Otto B, D'Amato M, Fried M,. Role of duodenal lipid and cholecystokinin a receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48: 347-55.
20. Cuperus P, Keeling PW, Gibnery MJ,. Eating patterns in functional dyspepsia: a case control study. Eur J Clin Nutr 1996; 50: 520-3.
21. Carvalho RV, Lorena SL, Almeida JR, Mesquita MA,. Food intolerance, diet composition, and eating patterns in functional dyspepsia patients. Dig Dis Sci 2010; 55: 60-5.
22. Tack J, Demedts I, Dehondt G, et al,. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122: 1738-47.
23. Moayyedi P, Soo S, Deeks J, et al,. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2008; 2: CD002096.
24. Lan L, Yu J, Chen YL, et al,. Symptom-based tendencies of Helicobacter Pylori eradication in patients with functional dyspepsia. World J Gastroenterol 2011; 17: 3242-7.
25. Mazzoleni LE, Sander GB, Francesconi CF, et al,. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171: 1929-33.
26. Cremonini F, Delgado-Aros S, Talley NJ,. Functional dyspepsia: drugs for new (and old) therapeutic targets. Best Pract Res Clin Gastroenterol 2004; 18: 717-33.
27. Moayyedi P, Shelly S, Deeks JJ, et al,. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; 4: CD001960.
28. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR,. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000; 47: 473-80.
29. Delattre M, Malesky M, Prinzie A,. Symptomatic treatment of nonulcer dyspepsia with cimetidine. Curr Therapeutic Res 1985; 37: 980-91.
30. Gotthard R, Bodemar G, Brodin U, Jonsson KA,. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 7-18.
31. Hadi S,. Clinical investigation of ranitidine in patients with gastritis. Clin Ther 1989; 11: 590-4.
32. Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB,. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 368-74.
33. Kato M, Watanabe M, Konishi S, et al,. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther 2005; 21 (Suppl. 2): 27-31.
34. Kelbaek H, Linde J, Eriksen J, Mungaard S, Moesgaard F, Bonnevie O,. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand 1985; 213: 281-7.
35. Muller P, Hotz J, Franz E, Simon B,. Ranitidine in the Treatment of Non-Ulcer Dyspepsia. A placebo-controlled study in the Federal Republic of Germany [Ranitidin in der Behandlung derNon-Ulcer-Dyspepsie. Eine placebo-kontrollierte Studie in der Bundesrepublic Deutschland]. Arzneimittelforschung/Drug Res 1994; 10: 1130-2.
36. Nesland AA, Berstad A,. Effect of cimetidine in patients with nonulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985; 20: 629-35.
37. Olubuyide IOOA, Ayoola EA, Okubanjo AO, Atoba MA,. Non-ulcer dyspepsia in Nigerians: clinical and therapeutic results. Scand J Gastroenterol 1986; 21 (Suppl. 124): 83-7.
38. Saunders JH, Oliver RJ, Higson DL,. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J (Clin Res Ed) 1994; 1986: 665-8.
39. Singal AK, Kumar A, Broor SL,. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin 1989; 11: 390-7.
40. Carvalhinhos A, Fidalgo P, Freire A, Matos L,. Cisapride compared with ranitidine in the treatment of functional dyspepsia. Eur J Gastroenterol Hepatol 1995; 7: 411-7.
41. Casiraghi A, Ferrara A, Lesinigo E,. Cimetidine vs antacids in non-ulcer dyspepsia. Curr Ther Res Clin Exp 1986; 39: 397.
42. Misra SP, Dwivedi M, Misra V, Agarwal SK,. Sucralfate versus ranitidine in non-ulcer dyspepsia: results of a prospective, randomized, open, controlled trial. Indian J Gastroenterol 1992; 11: 7-8.
43. Talley NJ, Meineche-Schmidt V, Paré P, et al,. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
44. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR,. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47: 473-80.
45. Bolling-Sternevald E, Lauritsen K, Aalykke C, Havelund T, Knudsen T, et al,. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002; 37: 1395-402.
46. Wong WM, Wong BC, Hung WK, Yee YK, Yip AW, et al,. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6.
47. Peura DA, Kovacs TO, Metz DC, Siepmaan N, Pilmer BL, Talley NJ,. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004; 116: 740-8.
48. van Zanten SV, Armstrong D, Chiba N, et al,. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol 2008; 101: 2096-106.
49. van Rensburg C, Berghöfer P, Enns R, Dattani ID, Maritz JF, et al,. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin 2008; 24: 2009-18.
50. Talley NJ, Vakil N, Lauritsen K, et al,. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther 2007; 26: 673-82.
51. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, et al,. Effects of proton pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007; 5: 172-85.
52. Vakil N, Laine L, Talley NJ, et al,. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008; 103: 1906-19.
53. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C,. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832-40.
54. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M,. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57: 740-6.
55. Hallerbäck BI, Bommelaer G, Bredberg E, et al,. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 959-67.
56. Talley NJ, Verlinden M, Snape W, et al,. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 1653-61.
57. Manabe N, Wong BS, Camilleri M,. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs 2010; 19: 765-75.
58. Lacy BE, Loew B, Crowell MD,. Prucalopride for chronic constipation. Drugs Today 2009; 45: 843-53.
59. Saarto T, Wiffen PJ,. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 4: CD005454.
60. Ford AC, Talley N, Schoenfeld PS, Quigley EM, Moayyedi P,. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
61. Talley NJ, Herrick L, Locke GR,. Antidepressants in functional dyspepsia. Expert Rev Gastroenterology Hepatol 2010; 4: 5-8.
62. Talley NJ, Camilleri M, Chitkara DK, et al,. Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: a randomized, double-blind, placebo-controlled study. Digestion 2005; 72: 97-103.
63. Choung RS, Cremonini F, Thapa P, Zinsmeister AR, Talley NJ,. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008; 20: 220-7.
64. Bouras EP, Talley N, Camilleri M, et al,. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008; 103: 2043-50.
65. Mertz H, Fass R, Kodner A, et al,. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160-5.
66. Otaka M, Jin M, Odashima M, et al,. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005; 21 (Suppl. 2): 42-6.
67. Wu JC, Cheong PK, Chan Y, et al,. A randomized, double-blind, placebo-controlled trial of low dose imipramine for treatment of refractory functional dyspepsia (FD). Gastroenterology 2011; 140 (Suppl. 1): S-50.
68. Talley NJ, Dennis EH, Schettler-Duncan VA, et al,. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 2454-9.
69. Tack J, Caenepeel P, Fischler B, et al,. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-35.
70. van Kerkhoven LA, Laheij RJ, Aparicio N, et al,. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomize, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6: 746-52.
71. Brennan BP, Fogarty KV, Roberts JL, et al,. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009; 24: 423-8.
72. Talley NJ, Locke GR 3rd, Herrick LM, et al,. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012; 33: 523-33.
73. Tack J, Masclee A, Heading R, et al,. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009; 21: 272-80.
74. Matsueda K, Hongo M, Tack J, et al,. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia-100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010; 22: 618-e173.
75. Gale JD, Houghton LA,. Alpha 2 Delta (α(2)δ) ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol 2011; 2: 28.
76. Stein DJ, Bruce Lydiard R, Herman BK, Mandel FS,. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009; 24: 126-32.
77. Eisenberg DM, Davis RB, Ettner SL, et al,. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280: 1569-75.
78. Barnes PM, Powell-Griner E, McFann K, Nahin RL,. Complementary and Alternative Medicine use Among Adults: United States, 2002. Hyattsville, MD: National Center for Health Statistics, 2004.
79. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J,. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion 2004; 69: 45-52.
80. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P,. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102: 1268-75.
81. Braden B, Caspary W, Borner N, Vinson B, Schneider ARJ,. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil 2009; 21: 632-9.
82. Holtmann G, Adam B, Haag S, et al,. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003; 18: 1099-105.
83. May B, Kohler S, Schneider B,. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000; 14: 1671-7.
84. Arora A, Sharma MP,. Use of banana in non-ulcer dyspepsia. Lancet 1990; 335: 612-3.
85. Kupcinskas L, Lafolie P, Lignell A, et al,. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: a prospective, randomized, double-blind, and placebo-controlled study. Phytomedicine 2008; 15: 391-9.
86. Bates S, Sjoden PO, Nyren O,. Behavioral treatment of non-ulcer dyspepsia. Scand J Behav Ther 1988; 17: 155-65.
87. Haug TT, Wilhelmsen I, Svebak S, Berstad A, Ursin H,. Psychotherapy in functional dyspepsia. J Psychosom Res 1994; 38: 735-44.
88. Hamilton J, Guthrie E, Creed F, et al,. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000; 119: 661-9.
89. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ,. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123: 1778-85.
90. Saad RJ, Chey WD,. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther 2006; 24: 475-92.
91. Traub RJ, Zhai Q, Ji Y, Kovalenko M,. NMDA receptor antagonists attenuate noxious and nonnoxious colorectal distention-induced Fos expression in the spinal cord and the visceromotor reflex. Neuroscience 2002; 113: 205-11.
92. Sengupta JN, Snider A, Su X, Gebhart GF,. Effects of kappa opioids in the inflamed rat colon. Pain 1999; 79: 175-85.
93. Delvaux M, Beck A, Jacob J, et al,. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 237-46.
94. Talley NJ, Choung RS, Camilleri M, et al,. Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 2008; 27: 1122-31.
95. Levin F, Edholm T, Schmidt PT, et al,. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 2006; 91: 3296-302.
96. Murray CD, Martin NM, Patterson M, et al,. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double-blind, placebo-controlled, cross-over study. Gut 2005; 54: 1693-8.
97. Ejskjaer N, Vestergaard ET, Hellstrom PM, et al,. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29: 1179-87.